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Abstract
Autoimmune progesterone dermatitis (APD) is a condition in which the menstrual cycle is
associated with a number of skin findings such as urticaria, eczema, angioedema, and others. In
affected women, it occurs 3–10 days prior to the onset of menstrual flow, and resolves 2 days into
menses. Women with irregular menses may not have this clear correlation, and therefore may be
missed. We present a case of APD in a woman with irregular menses and urticaria/angioedema for
over 20 years, who had not been diagnosed or correctly treated due to the variable timing of skin
manifestations and menses. In addition, we review the medical literature in regards to clinical
features, pathogenesis, diagnosis, and treatment options.
Introduction
While many women complain of worsening acne and
water retention during their menstrual cycle, there exist a
small number in whom the menstrual cycle is associated
with a variety of other skin manifestations such as urti-
caria, eczema, folliculitis, and angioedema. This condi-
tion is known as autoimmune progesterone dermatitis
(APD) due to the fact that progesterone is most frequently
identified as the etiologic agent. In women with irregular
menses, the diagnosis may remain elusive for years. We
present a case of APD, and review the current literature in
regards to clinical features, pathogenesis, diagnosis, and
treatment options.
Case
A 33y/o woman with a history of endometriosis presented
with complaints of chronic urticaria. The patient noted
that the urticaria began at the age of 12, and did not seem
to have any obvious trigger. Each individual lesion would
last from 12–24 hours, and the entire episode would last
5–10 days. Lesions would usually start on the chest and
then spread over the entire body. She had seen multiple
physicians, including allergists and dermatologists, and
had been treated with a variety of medications including
certirizine, desloratadine, hydroxyzine, montelukast, ran-
itidine, and diphenhydramine without relief. Prednisone
at high doses would provide temporary relief, and she had
required multiple courses of prednisone over the past 20
years. In addition, she complained of occasional
angioedema, usually at the same time as the hives but
occasionally occurring when hives were not present. The
patient also had acne that had been very difficult to con-
trol since her teenage years, and she noted that the acne
would also respond to prednisone.
Multiple lab tests over the years had been unremarkable.
These included SSA/SSB, anti-Smith, ACE level, C3/C4,
hepatitis B, ANA, anti double-stranded DNA, immu-
noglobulins, SPEP, C1 esterase inhibitor level and func-
tion, chemistry panel, liver tests, TSH, T4, thyroid
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antibodies, rheumatoid factor, ESR, and CBC. Skin biopsy
of a lesion had been read as "chronic urticaria".
Upon further questioning, it was learned that due to the
patient's endometriosis, she had very irregular menstrual
cycles in terms of length and timing. It was determined
that the hives and/or angioedema would begin approxi-
mately 4 days prior to the onset of menses, and would last
about 2 days into menses. The symptoms would not occur
with every episode of menses. The patient's acne would
often occur on her face during the urticarial episodes. Of
note, the patient had 2 children, and during each preg-
nancy her hives, acne, and angioedema had been mark-
edly improved. Because of her endometriosis, she had
been started on Depo-Provera (medroxyprogesterone ace-
tate) in her twenties. After 1 injection, she developed
severe hives that lasted over 2 months and required mul-
tiple courses of prednisone. Due to the urticaria, Depo-
Provera was discontinued after one injection. As the
patient complained of acne, Ortho Tri-Cyclen (norgesti-
mate/ethinyl estradiol) was initiated by her dermatolo-
gist. This treatment modality did not have any effect on
the urticaria, angioedema, or acne.
The patient was evaluated in our clinic. Physical examina-
tion was essentially normal, and no hives were noted.
Allergy skin testing was performed with progesterone 50
mg/mL in normal saline. Prick test was normal, but a full
strength intradermal test revealed a 7 mm wheal with ery-
thema. The histamine control showed a 9 mm wheal with
erythema, and saline control was negative for wheal and
erythema. Two healthy controls also underwent intrader-
mal testing to exclude irritant reaction, and were found to
be negative
Based on the above results, the patient was diagnosed
with autoimmune progesterone dermatitis. The patient
was started on a GnRH agonist (nafarelin acetate nasal
spray, 200 mcg twice a day). Within one month, she noted
dramatic improvement in her urticaria and angioedema.
Acne was still occasionally present, but much improved.
She did complain of mild hot flashes, but felt these were
tolerable.
Discussion
In a small group of women, the menstrual cycle has been
associated with a spectrum of dermatologic diseases
including eczema, erythema multiforme, stomatitis,
papulopustular lesions, folliculitis, angioedema, urticaria,
and others (Table 1) [1-8]. As progesterone sensitivity has
been the most commonly identified cause, dermatologic
diseases associated with the menstrual cycle have been
labeled autoimmune progesterone dermatitis (APD) [4].
The first documented case of APD was in 1921, in which
a patient's premenstrual serum caused acute urticarial
lesions. In addition, it was shown that the patient's pre-
menstrual serum could be used to desensitize and
improve her symptoms [9]. Since 1921, approximately 50
cases of APD have been published in the medical
literature.
Clinical Features
The clinical symptoms of APD (eczema, urticaria,
angioedema, etc.) usually begin 3–10 days prior to the
onset of menstrual flow, and end 1–2 days into menses.
Severity of symptoms can vary from nearly undetectable
to anaphylactic in nature, and symptoms can be progres-
sive [10,11]. There are no specific histological features on
biopsy in APD [12]. The age of onset is variable, with the
earliest age reported at menarche [13]. Some studies have
noted that a majority of patients had taken an oral contra-
ceptive (OCP) prior to the onset of APD [14], but multiple
cases exist in which women have never been exposed to
exogenous progesterone [15-17].
The symptoms of APD correlate with progesterone levels
during the luteal phase of the menstrual cycle.
Progesterone begins to rise 14 days prior to the onset of
menses, peaks 7 days prior to menses, and returns to a low
baseline level 1–2 days after menses begins. In studies
where an etiologic agent has been sought, progesterone
has been found most frequently. However, estrogen, pros-
tacyclin, and gonadotropin levels have correlated with
symptoms in some cases [18-21].
Symptoms may first appear, improve, or worsen during
pregnancy and the peripartum period [2,22-24]. In addi-
tion, APD during pregnancy has been associated with
spontaneous abortions [2,25]. Pregnancy is associated
with an increase of maternal progesterone levels, which
may explain the initiation or worsening of symptoms. In
regards to an improvement of symptoms during preg-
nancy, a number of theories have emerged. Explanations
include a slow rise of progesterone during pregnancy that
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acts as a method of desensitization, a decrease in maternal
immune response during pregnancy, or an increased pro-
duction of anti-inflammatory glucocorticoids [13,25,26].
Pathogenesis
The exact pathogenesis of APD is unknown. If exogenous
progesterones (i.e. OCPs) are initially used, it is conceiva-
ble that uptake by antigen presenting cells and presenta-
tion to TH2 cells could result in subsequent IgE synthesis;
however this mechanism would not explain the patho-
genesis in patients such as ours who have the onset of
APD prior to exogenous progesterone exposure. Some
authors have suggested that hydrocortisone or 17-α-
hydroxyprogesterone have cross-sensitivity with proges-
terone and may cause initial sensitization, but this has not
been observed in all studies [27,28].
To further delineate the pathogenesis, antibodies against
progesterone have been investigated. Using immunofluo-
rescent techniques and basophil degranulation tests, stud-
ies have found that such antibodies do exist in certain
patients with APD [1,13,29]. However, negative results
looking for antibodies have also been reported [24]. In
addition, skin test results with progesterone have shown
immediate reactions (within 30 minutes), delayed reac-
tions (24–48 hours later), and reactions with features of
both immediate and delayed features [13,14,30,31]. This
presumably indicates both type I and type IV hypersensi-
tivity reactions. Progesterone has also been reported to
have a direct histamine releasing effect on mast cells, yet
very little research has been done to support this hypoth-
esis [32]. Additionally, one study found an in vitro
increase of an interferon-γ release assay, possibly implying
a role for TH1-type cytokines in APD [33].
Eosinophils may also be involved in the pathogenesis of
APD. Eosinophilia has been correlated with cutaneous
symptoms in some cases, and studies have found a
decrease in total eosinophil count after therapy
[13,29,34]. Whether increased eosinophils are a response
to cytokines from lymphocytes or play a primary mecha-
nistic role in APD remains to be determined.
Diagnosis
The diagnosis of APD requires an appropriate clinical his-
tory accompanied by an intradermal injection test with
progesterone. An aqueous suspension or aqueous alcohol
solution of progesterone is the preferable vehicle of test-
ing as progesterone in oil can cause an irritant reaction
[35], though many published case reports have used pro-
gesterone in oil for testing. Various authors have advo-
cated different amounts of progesterone or
medroxyprogesterone to be used for testing [12,33,36]. As
had been done in some prior studies, the patient pre-
sented here was tested with progesterone in aqueous solu-
tion at a concentration of 50 mg/mL.
As mentioned above, APD may be due to an immediate or
delayed hypersensitivity reaction. Therefore, intradermal
testing may not become positive until 24–48 hours later
[14,24]. In addition, some authors have advocated patch
testing with progesterone to further evaluate for a hyper-
sensitivity reaction [33]. Of note, intradermal testing has
been negative in some patients with typical clinical symp-
toms of APD and who improved after APD treatment
[2,3,24].
Some authors have recommended further tests to evaluate
the immunologic evidence in APD. These include circulat-
ing antibodies to progesterone, basophil granulation
tests, direct and indirect immunofluorescence to luteiniz-
ing cells of the corpus luteum, in vitro interferon-γ release,
and circulating antibodies to 17-α-hydroxyprogesterone
[1,7,13,29,33,36]. However, most case reports in the
medical literature do not routinely check for serologic evi-
dence of APD, and when checked these markers have not
always been found to be reliable. This is most likely due
to the fact that, as mentioned above, the pathogenesis of
APD is incompletely understood.
Treatment
Autoimmune progesterone dermatitis is usually resistant
to conventional therapy such as antihistamines. The use
of systemic glucocorticoids, usually in high doses, has
been reported to control the cutaneous lesions of APD is
some studies, but not in others [3,10,37]. Early reports of
APD describe attempts of progesterone desensitization,
and some authors even attempted injections derived from
the corpus luteum [18,24,38]. However, results were usu-
ally temporary, and such methods of treatment have now
fallen out of favor.
Current therapeutic modalities often attempt to inhibit
the secretion of endogenous progesterone by the suppres-
sion of ovulation. Table 2 lists some of the pharmacologic
strategies used in APD. Oral contraceptives (OCPs) are
often tried as initial therapy, but have had limited success,
possibly due to the fact that virtually all OCPs have a pro-
gesterone component. Conjugated estrogens have also
been used in the treatment of APD. These did show
improvement in many of the patients, but often required
high doses [2,16,22]. However, due to the increased risk
of endometrial carcinoma with unopposed conjugated
estrogens, this treatment is not commonly used today
[39].
Various other therapy modalities are currently used in
APD, and there is no clear treatment of choice. GnRH ago-
nists, such as buserelin and triptorelin, have been used toClinical and Molecular Allergy 2004, 2:10 http://www.clinicalmolecularallergy.com/content/2/1/10
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induce remission of symptoms by causing ovarian sup-
pression [7,11,15]. However, side effects include symp-
toms of estrogen deficiency (hot flashes, vaginal dryness,
decreased bone mineral density), and estrogen supple-
mentation may be needed [40]. Alkaylated steroids such
as stanozol have been used to successfully suppress ovula-
tion, sometimes in combination with chronic low doses
of corticosteroids [37]. Side effects of alkaylated steroids
include abnormal facial or body hair growth, hepatic dys-
function, and mood disorders, any of which may limit
their use. To decrease the risk of side effects, some authors
have recommended using the alkaylated steroid only in
the perimenstrual period [37]. Another therapeutic
option used in APD has been the antiestrogen tamoxifen,
which also can suppress ovulation [3,5]. As with GnRH
agonists, patients on tamoxifen may experience symp-
toms of estrogen deficiency. In addition, tamoxifen has
been associated with an increased risk of venous throm-
bosis and cataract formation. In some patients with unre-
mitting symptoms of APD, bilateral oopherectomy has
been required [10,15,24]. While this definitive treatment
has been successful in controlling symptoms, today it is
rarely used before all medical options have been
exhausted.
Conclusion
Autoimmune progesterone dermatitis is a condition seen
in a small number of women who present with eczema,
erythema multiforme, stomatitis, papulopustular lesions,
folliculitis, angioedema, urticaria, and other skin manifes-
tations in relation to the menstrual cycle. It is usually seen
3–10 days prior to the onset of menstrual flow, but may
be difficult to recognize in women with irregular menses.
The exact pathogenesis is unknown, and is thought to
involve a hypersensitivity reaction to progesterone. The
diagnosis of APD is made by an appropriate clinical his-
tory accompanied by an intradermal injection test with
progesterone. Current treatment modalities often attempt
to inhibit the secretion of endogenous progesterone, but
may be unsuccessful. More research is needed into the
pathogenesis of APD to most appropriately care for these
patients.
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